Wedbush Issues Positive Outlook for BCRX Earnings

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) – Investment analysts at Wedbush upped their Q3 2025 earnings per share (EPS) estimates for shares of BioCryst Pharmaceuticals in a report issued on Monday, August 4th. Wedbush analyst L. Chico now expects that the biotechnology company will earn $0.07 per share for the quarter, up from their previous forecast of $0.04. Wedbush currently has a “Outperform” rating and a $18.00 target price on the stock. The consensus estimate for BioCryst Pharmaceuticals’ current full-year earnings is ($0.36) per share. Wedbush also issued estimates for BioCryst Pharmaceuticals’ Q4 2025 earnings at $0.04 EPS and FY2028 earnings at $1.05 EPS.

A number of other equities research analysts also recently issued reports on BCRX. Royal Bank Of Canada reissued an “outperform” rating and set a $13.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Monday, June 30th. Bank of America lifted their target price on BioCryst Pharmaceuticals from $13.00 to $15.00 and gave the company a “buy” rating in a research report on Tuesday, July 1st. Barclays upped their price target on BioCryst Pharmaceuticals from $8.00 to $11.00 and gave the stock an “equal weight” rating in a research report on Wednesday, May 7th. Wall Street Zen raised BioCryst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, July 26th. Finally, JPMorgan Chase & Co. boosted their price objective on BioCryst Pharmaceuticals from $10.00 to $13.00 and gave the company an “overweight” rating in a research note on Tuesday, May 6th. One analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, BioCryst Pharmaceuticals currently has an average rating of “Buy” and an average price target of $16.70.

BioCryst Pharmaceuticals Trading Up 2.9%

Shares of NASDAQ BCRX opened at $8.60 on Wednesday. BioCryst Pharmaceuticals has a 12-month low of $6.01 and a 12-month high of $11.31. The firm has a market capitalization of $1.80 billion, a price-to-earnings ratio of -47.78, a price-to-earnings-growth ratio of 1.27 and a beta of 1.10. The firm has a 50 day moving average of $9.42 and a 200 day moving average of $8.74.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings results on Monday, August 4th. The biotechnology company reported $0.15 EPS for the quarter, beating the consensus estimate of $0.03 by $0.12. The business had revenue of $163.35 million for the quarter, compared to analysts’ expectations of $149.59 million. During the same period in the previous year, the company earned ($0.06) EPS. BioCryst Pharmaceuticals’s revenue for the quarter was up 49.5% compared to the same quarter last year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Lazard Asset Management LLC increased its stake in BioCryst Pharmaceuticals by 68.1% in the 4th quarter. Lazard Asset Management LLC now owns 161,516 shares of the biotechnology company’s stock worth $1,214,000 after acquiring an additional 65,420 shares during the last quarter. Raymond James Financial Inc. bought a new stake in shares of BioCryst Pharmaceuticals in the 4th quarter valued at approximately $80,000. Allspring Global Investments Holdings LLC purchased a new position in shares of BioCryst Pharmaceuticals in the 1st quarter worth approximately $79,000. Jupiter Asset Management Ltd. increased its position in shares of BioCryst Pharmaceuticals by 82.4% during the 1st quarter. Jupiter Asset Management Ltd. now owns 2,148,969 shares of the biotechnology company’s stock valued at $16,117,000 after purchasing an additional 971,040 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in BioCryst Pharmaceuticals by 3.0% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 401,111 shares of the biotechnology company’s stock worth $3,016,000 after buying an additional 11,581 shares during the last quarter. Institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.